Fragment Based Identification of Phosphatase Inhibitors
Phosphatases are broadly introduced as an enzyme class with therapeutic implications in a variety of disease areas. A substrate-based fragment approach is used to identify novel phosphatase inhibitors of first Mycobacterium tuberculosis protein tyrosine phosphatase PtpA, for potential therapeutic implications in tuberculosis, then for striatal-enriched protein tyrosine phosphatase (STEP), which has therapeutic implications for Alzheimer's disease. Finally, benzopentathiepins and seleninic acids are investigated as redox-reversible inhibitors of STEP. Aditionally, a method for the asymmetric additions of Knochel-type benzyl zinc reagents to N-tert-butanesulfinyl aldimines is described.